Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06839066 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy

Name: A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy — clinical trial record (NCT06839066)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorShanghai Henlius Biotech

Started2025-04-02

View on ClinicalTrials.gov ↗

Amendment history

2025-11-18

Not Yet Recruiting→Recruiting Study Identification, Study Status, Oversight, Study Design, Contacts/Locations v1

Trial statusNot Yet Recruiting→Recruiting

Start dateestimated 2025-03-31→confirmed 2025-04-02

Enrollment target90→70

Study sites0→15

Study titlerevised

A Phase II Study to Evaluate HLX43 in Subjects ~~with~~With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy

2025-02-18

Original filing

Shanghai Henlius Biotech

56 trials monitored

See all monitored trials

Head & Neck Cancer

2,051 trials monitored

See 116 trials at risk

The study is to explore the reasonable dosage and to evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in patients with recurrent/metastatic Nasopharyngeal Carcinoma (NPC) who failed or are intolerant to second-line herapy.

Trial Details

NCT Number	NCT06839066
Lead Sponsor	Shanghai Henlius Biotech
Conditions	Nasopharyngeal Carcinoma (NPC)
Enrollment	70 participants
Start Date	2025-04-02
Primary Completion	2026-11-22 (estimated)
Study Completion	2027-11-22 (estimated)
Updated on ClinicalTrials.gov	2025-11-24